Sorrento Therapeutics Inc (SRNE)

[dia76ca]

TEN February/March potential news items/34 top programs/70+ total pipeline.
1. ABIVERTINIB $61 Billion global market partnership(s). There will be multi-billion upfront, milestone and royalty payments. They announced partnering intentions about 7 months ago! Remember the Genentech/Roche scenario!
2. SCILEX SPINOFF. More SEMDEXA data is due any day. This new treatment could gross $6-10 billion annually in the US alone!.
3. COVISTIX REVENUE STREAM. Sales have recorded in Q4 of 2021 and are ramping up in Q1 of 2022. Mexico leads the way and Europe, Central and South America, Canada, Japan and the US will follow. 30 million monthly test production near term!
4. COVIDROPS, COVI-MSC, COVISHIELD, SEMDEXA, ABIVERTINIB(cancer and Covid) news is expected in Q1 2022 and more EUA's. SEMDEXA and ABIVERTINIB revenue in 2H of 2022?
5. COVIDROPS is in phase 2 in the US and UK. Soon to enter a pediatric trial in Mexico. An Interim analysis of the UK out-patient trial any day.
6. COVI-MSC is in phase 2 trials in the US and Brazil The Brazilian study is pivotal. In Brazil it is followed by a trial for long-haul Covid patients.
7. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). A prestigious European journal made it front page news. This could enter the clinic in Q1 or Q2.
8. In Cancer Sorrento has more than 10 fully human antibodies in the clinic or late pre-clinical(PD-1, PD-L1, CD38, CD123, CD47,BCMA, TROP2, LAG3, CTLA-4 and CD137). An allogenic DAR-T, an anti-TROP2 ADC and a second generation oncolytic virus(Seprehvec) will enter the clinic with several ADNAB(Mayo Clinic) drugs.
9. Non-opioid RTX is in phase 2 for arthritic knee pain and will enter phase 2 for epidural delivery for severe cancer pain in Q1.
10. Sofusa will report on a phase 1 arthritis treatment in Q1. Also is being tested in delivering cancer therapies including a collaboration with the Mayo Clinic to test lymphatic delivery.
And have a look at the top 34 portfolio items from the SRNE website. No wonder Blackrock holds over 20 million shares!
https://sorrentotherapeutics.com/research/pipeline/
And here is a look at the entire pipeline.(70+prorams)
***PHASE 3, close to EUA or close to market (12 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered.China NDA filed for cervical cancer.
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico, Brazil and Europe...15 millions shipped to Mexico. WHO and Canada coming soon. DOD CRADA
11. Sofusa Enbrel phase 1b
12. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS phase 2 US, UK and Mexico. EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential to prevent intubation Brazil and US.
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's are producing revenue in Mexico and Brazil. COVISTIX production ramping up to over 30 million per month near term. Outstanding ABIVERTINIB(COVID) results in Brazil and US. Giant ABIVERTINIB centered partnership(s) coming soon! And SEMDEXA sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!